Title :

Efficacy of lanreotide 120 mg primary therapy on tumor shrinkage and ophthalmologic symptoms in acromegaly after one month.

Author(s) :

Benderradji, Hamza [Auteur]
Lille Neurosciences & Cognition - U 1172 [LilNCog]
Vernotte, E. [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Soto-Ares, Gustavo [Auteur]
Maladies RAres du DEveloppement embryonnaire et du MEtabolisme : du Phénotype au Génotype et à la Fonction - ULR 7364 [RADEME]
Woillez, J. P. [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Jannin, Arnaud [Auteur]
Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers = Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Perbet, Romain [Auteur]
Lille Neurosciences & Cognition - U 1172 [LilNCog]
Karnoub, Melodie-Anne [Auteur]
Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U 1192 [PRISM]
Soudan, B. [Auteur]
Assaker, Richard [Auteur]
Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U 1192 [PRISM]
Buee, Luc [Auteur]
Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer - U837 [JPArc]
Prevot, Vincent [Auteur]
Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer - U837 [JPArc]
Maurage, Claude-Alain [Auteur]
Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer - U837 [JPArc]
Pigny, Pascal [Auteur]
Miniaturisation pour la Synthèse, l’Analyse et la Protéomique - UAR 3290 [MSAP]
Vantyghem, Marie-Christine [Auteur]
Recherche translationnelle sur le diabète - U 1190 [RTD]
Merlen, Emilie [Auteur]
Service Endocrinologie, diabétologie, maladies métaboliques et nutrition [LILLE - Endocrino]
Cortet, C. [Auteur]

Journal title :

Clinical Endocrinology

Publisher :

Wiley

Publication date :

2022-04-28

ISSN :

0300-0664

English keyword(s) :

acromegaly
first-generation somatostatin analogues
lanreotide
MRI
optic chiasm compression
treatment response
visual field defects

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

IntroductionFew studies have attempted to evaluate the early efficacy of first-generation somatostatin analogues in somatotroph macroadenomas.ObjectiveTo investigate the short-term efficacy of primary therapy with lanreotide ...
Show more >IntroductionFew studies have attempted to evaluate the early efficacy of first-generation somatostatin analogues in somatotroph macroadenomas.ObjectiveTo investigate the short-term efficacy of primary therapy with lanreotide 120 mg at 1 and 3 months on tumour shrinkage and ophthalmologic symptoms in newly diagnosed patients with acromegaly.Design and PatientsThis single-centre retrospective study included 21 patients with de novo acromegaly resulting from pituitary macroadenoma, with optic chiasm compression (Grade ≤ 2) and/or cavernous sinus invasion, treated with a monthly injection of lanreotide 120 mg. Clinical, hormonal, ophthalmologic and magnetic resonance imaging scan evaluations were conducted after the first and the third months of treatment.ResultsTumour volume reduction was more pronounced at 1 month; mean volume change: −31.4 ± 19.5%, p < .0001 than between the first and third month of treatment; mean volume reduction: −20.6 ± 13.4%, p = .0009. The mean volume change between baseline and the third month was − 46.4 ± 21.6, (p < .0001). A significant volume reduction (≥25%) was observed in 61.9% of individuals (13/21) at the first month. Among 14 individuals with optic chiasm compression and visual field defects, visual field normalization or improvement were observed in seven cases (50%), stabilization in four cases (28.5%), and mild worsening in three cases (21.4%) at 1 month. The decrease in growth hormone and IGF-1 serum values was significant at 1 month.ConclusionsPrimary treatment with lanreotide 120 mg in patients with somatotroph macroadenomas provides early significant tumour shrinkage with rapid improvement of visual symptoms at the end of the first month in 50% of patients.Show less >

Language :

Français

Peer reviewed article :

Oui

Audience :

Internationale

Popular science :

Non

Collections :

• Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER) - UMR 9020 - UMR 1277

Source :

Harvested from HAL